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DObjectives: Our model of a systemic–pulmonary shunt exhibits enhanced reactivity of pulmonary arteries
contralateral to a localized shunt between the left lower lobe pulmonary artery and aorta relative to those of
ipsilateral or control pulmonary arteries 48 hours after anastomosis. We examined the contribution of nitric oxide,
cyclooxygenase, lipoxygenase, or cytochrome P450 production to mediating this enhanced reactivity.
Methods: We created a surgical end-to-side anastomosis of the left lower lobe pulmonary artery to the aorta.
Forty-eight hours later, we tested tension of pulmonary artery rings from the right and left lower lobes for
contraction to the thromboxane mimetic U46619 in the presence of vehicle or inhibitors of nitric oxide synthase,
cyclooxygenase, cytochrome P450, or lipoxygenase. Western blots of pulmonary artery homogenates were
probed for endothelial nitric oxide synthase or isoforms metabolizing arachidonic acid. Eicosanoid products
from intact pulmonary artery rings were detected using labeled arachidonic acid and high-performance liquid
chromatography separation.
Results: Enhanced reactivity of unshunted right pulmonary arteries over that of left pulmonary arteries from
high-flow hosts was not eliminated by inhibitors of nitric oxide synthase, cyclooxygenase, cytochrome P450.
Treatment with 2 different lipoxygenase inhibitors, nordihydroguaiaretic acid and cinnamyl-3,4-dihydroxy-a-
cyanocinnamate, closed the difference in contractility of shunted and unshunted pulmonary arteries. Pulmonary
arteries contralateral to shunts metabolized arachidonic acid to 12-hydroxyeicosatetraenoic acid in greater quan-
tities than analogous pulmonary arteries from the experimental left or control pulmonary arteries.
Conclusions: Forty-eight hours after anastomosis, enhanced reactivity of contralateral pulmonary arteries is
attributable in part to increased lipoxygenase products as opposed to nitric oxide or other eicosanoid products.
(J Thorac Cardiovasc Surg 2011;141:425-31)High flow and pressure are reported to increase or decrease
elaboration of both prodilatory and proconstrictive factors in
the pulmonary circulation.1-3 Variability in these findings
has been attributed to differences in the duration of exposure
to high flow rates, with the implication that a shift from
predominance of provasodilatory to proconstrictive factors
occurs at some point after initiation of high flow. The effect
of a localized anastomosis on endothelium-derived products
of pulmonary arteries not directly exposed to high flow or
pressure in vivo has not been examined to our knowledge.
We developed a model of localized high flow to the left lower
lobe and examined reactivity of pulmonary arteries from ipsi-
lateral and contralateral pulmonary arteries 48 hours later.Wee Departments of Pharmacology & Toxicology,a Surgery,b and Medicine,c
cal College of Wisconsin, Milwaukee Wis.
pport from the National Heart, Lung, and Blood Institute: grants HL068627
L-49294 (to E.R.J.).
ures: Authors have nothing to disclose with regard to commercial support.
d for publication Nov 30, 2009; revisions received June 22, 2010; accepted for
cation July 5, 2010; available ahead of print Nov 15, 2010.
for reprints: Elizabeth R. Jacobs, MD, MBA, Pulmonary and Critical Care
ion, Department of Medicine, Medical College of Wisconsin, 9200 W. Wis-
n Ave, Milwaukee WI 53226 (E-mail: ejacobs@mcw.edu).
23/$36.00
ht  2011 by The American Association for Thoracic Surgery
016/j.jtcvs.2010.07.007
The Journal of Thoracic and Cachose the time frame of 48 hours because changes in protein
expression potentially related to differences in vasoactivity
should reasonably be expected by this time, and pilot experi-
ments supported changes in vascular reactivity within 2 days.
Our experiments demonstrated enhanced endothelium-
dependent reactivity of pulmonary arteries contralateral to
the shunt4 relative to that of control and ipsilateral pulmonary
arteries. We hypothesized that either decreased synthesis of
a vasodilatory product or enhanced release of a constrictor
from right (contralateral) pulmonary arteries would account
for this difference in reactivity to thromboxane agonists. Be-
cause nitric oxide (NO) and metabolites of arachidonic acid
are known to modulate pulmonary vascular tone, we blocked
the synthesis of these products to test the contribution of these
mediators to enhanced constriction of unshunted pulmonary
arteries.METHODS AND MATERIALS
Materials
The following materials were used: nordihydroguaiaretic acid (NDGA)
(N-5023; Sigma–Aldrich, St Louis, Mo); indomethacin (I-7378, Sigma–
Aldrich), L-Ng-monomethylarginine (L -NMMA, ALX-106-001-M025; Ax-
xora, LLC, San Diego, Calif); cinnamyl-3,4-dihydroxy-a-cyanocinnamate
(CDC) (EI211-0010, Biomol International, LP, Plymouth Meeting, Pa);




CYP ¼ cytochrome P450
DDMS ¼ dibromo-dodecynyl-methylsulfimide
eNOS ¼ endothelial nitric oxide synthase
HEPES ¼ N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid
HETA ¼ 12-hydroxyeicosatrienoic acid
IC50 ¼ inhibitory concentration of 50%
L-NMMA ¼ L -Ng-monomethylarginine
LOX ¼ lipoxygenase
NDGA ¼ nordihydroguaiaretic acid
PG ¼ prostaglandin
THETA ¼ trihydroxyeicosatrienoic acid
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D5-lipoxygenase (LOX) antibody (5-LOX Ab; 160402; Cayman Chemical,
Ann Arbor, Mich); 12-LOX Ab (160304; Cayman Chemical); 15-LOX1
Ab (H-235: sc-32940; Santa Cruz Biotechnology, Inc, Santa Cruz, Calif);
and 15-LOX2Ab (H-55: sc-67142; Santa CruzBiotechnology, Inc); endothe-
lial nitric oxide synthase (eNOS) Ab (sc-7271, Santa Cruz Biotechnology,
Inc); beta actin Ab (Sigma A2228); arachidonic acid (56028; Nuchek Prep,
Inc, Elysian, Minn); [14C (U)]-arachidonic acid (specific activity 920 mCi/
mmol) (NEN Radiochemcials, Perkin Elmer, Waltham, Mass); ECL Plus de-
tection reagent (RPN 2133, Amersham Biosciences, Piscataway, NJ).Surgical Anastomosis
For details of this procedure, see our companion paper and our previous
publication.5All animals received care in compliancewith the ‘‘Guide for the
Care andUse of LaboratoryAnimals’’ published by theNational Institutes of
Health. A thoracotomy was performed and the left lower lobe pulmonary ar-
tery ligated proximally. The distal left lower lobe pulmonary arterywas sewn
end to side to the descending thoracic aorta. Measurements of flow through
the shunt were obtained immediately before and after creation of the shunt as
well as at the time of harvest. ‘‘High flow’’ was defined as flow rates through
the anastomoses at harvest that were either twice that of the right lower lobe
pulmonary artery or twice that of the left lower lobe pulmonary artery before
the anastomosis. In some animals, low-flow shunts were deliberately created
by anastomosing the left lower lobe pulmonary artery to an opening created
by a 3-mm instead of a 5-mmaortic punch.Harvest flows less than half that of
the unshunted right lower lobe pulmonary artery or the left lower lobe pulmo-
nary artery before shunt creation we defined as ‘‘low flow.’’
Harvesting Lungs, Dissecting Pulmonary Arteries
Two days after the creation of the anastomosis, pigs were sedated and
intubated. A thoracotomy was performed and flow rates of the anastomosed
left pulmonary arteries were determined. After flow measurements, animals
were humanely killed through exsanguination under deep anesthesia. The
heart and lungs were removed en bloc and then transported on ice to the
laboratory where pulmonary arteries 1 to 2 mm in diameter were dissected
microscopically for studies.Ring Tension Studies
Tension measurements were obtained according to methods previously
published by us.6 Pulmonary artery rings, microdissected free of adherent
lung tissue and 1- to 2-mm in diameter, were held in ice-cold physiologic426 The Journal of Thoracic and Cardiovascular Surgsaline solution (in mmol/L: NaCl 130, CaCl2 2.5; NaHCO3 15; MgSO4
1.2; NaH2PO4 1.2; KCl 4.7; glucose 5.5; HEPES (N-2-hydroxyethylpiper-
azine-N’-2-ethanesulfonic acid) 10; and ethylenediaminetetraacetic acid
0.026; pH 7.4) until use. Rings were mounted on tungsten wires connected
to a force displacement transducer (model FT03E; Grass Instruments, West
Warwick, RI) for continuously measuring isometric tension. The apparatus
was immersed in pH-adjusted, oxygenated physiologic saline solution
(95% oxygen and 5% carbon dioxide) at 37C. Rings from shunted and
unshunted lobes were preloaded with 0.4 g of passive tension to maximize
active tension development and then equilibrated for an additional 30 min-
utes before the studies began. Concentration responses to the thromboxane
mimetic U-46619 (eg, reference 5), an established pulmonary artery vaso-
constrictor, were used to determine the tone of the pulmonary artery rings.
Western Analysis
Western analyses were performed according to our previously published
methods.6 Protein determination in crude homogenates of pulmonary
arteries 1- to 3-mm in diameter was estimated using a Bio-Rad protein assay
kit (Bio-Rad Laboratories, Berkeley, Calif). Specific antibodies for 5-LOX,
12-LOX, 15-LOX1, 15-LOX2, or eNOS were matched with secondary an-
tibodies and visualized with ECL Plus detection reagent. Blots were also
probed for actin to normalize for protein loading. The blots were scanned
using an Alpha Image 220 Analysis System (Alpha Innotech Corporation,
San Leandro, Calif), and the relative densities of the bands from the same
blot were compared.
Metabolism of [14C]-arachidonic acid in ex vivo pulmo-
nary arteries. These studies were completed using methods previ-
ously published by us.7 Pulmonary arteries 1- to 3-mm in diameter were
dissected, cleaned, and cut into 2- to 3-mm rings in HEPES buffer
(mmol/L): 10 HEPES, 150 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 6 glucose,
pH 7.4. Rings were incubated at 37C in 5 mL HEPES with [14C]-arachi-
donic acid (0.5 mCi, 107 mol/L). After 5 minutes, A23187 (105 mol/L)
was added. The reaction was stopped after 10 minutes with ethanol (15%
final concentration), and the samples were extracted using Bond Elut C18
octadecylsilyl columns (Varian, Inc, San Carlos, Calif). The extracts were
analyzed by reverse phase high-performancy liquid chromatography using
a Nucleosil C18 (5 m, 4.63 250mm) column (Varian, Inc). The solvent sys-
tem consisted of a 40-minute linear gradient (flow rate ¼ 1 mL/min) from
50% solvent B (acetonitrile with 0.1% glacial acetic acid) in solvent A (de-
ionized water) to 100% solvent B. Column effluent was collected in 0.2-mL
fractions, and the radioactivity was determined. Identification of metabolites
was based on elution times identical to that of authentic standards.
Statistical Analyses
Experimental results for individual test conditions from 4 to 5 rings from
the left and an equal number from the right of a single host were averaged for
each ‘‘n.’’ Therefore, the ‘‘n’’s provided in the results section represent in-
dividual animals rather than individual pulmonary artery rings. Values are
expressed as the means  standard errors. Comparisons between controls
and treatments (or left vs right) were analyzed by 2-way repeated measures
analysis of variance followed by post hoc tests when permitted. Values for
paired studies (eg, left lower lobe pulmonary artery tension to a specific con-
centration of U46619 with and without CDC or NDGA) were compared by
the t test.
RESULTS
Difference in Right and Left Pulmonary Artery
Contractility to U-46619 Is Not Accounted for by
NOS Activity or Expression
Pulmonary arteries from the unshunted right lower lobes
of high-flow pigs exhibited higher tension to U46619 than
matched left pulmonary arteries distal to the shunt 48 hoursery c February 2011
FIGURE 1. The inset schematic denotes the sources and effects of NO on pulmonary vascular tone and site of action of L-NMMA. Rings from high-flow pigs
(A) or low-flow pigs (B) were treated with L-NMMA (103 mol/L) or vehicle, allowed to equilibrate for 30 minutes, and then a concentration response to
U46619 was obtained. See legends for identification of treatment groups. Single asterisks denote concentration curves of left and right pulmonary arteries
that are different one from the other based on 2-way repeated measures analysis of variance (P<.05). Double asterisks indicate differences in response curves
of pulmonary arteries treated with L-NMMA relative to that of pulmonary arteries treated with vehicle. L-NMMA increased basal tension and shifted the con-
centration response to U46619 of all pulmonary arteries up and to the left, regardless of the flow state of the shunt. PA, Pulmonary artery; L-NMMA, L-Ng-
monomethylarginine; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase.
FIGURE 2. Western blots for detection of eNOS immunospecific protein
in homogenized pulmonary artery vessels from left or right lower lobe of 7
high-flow pigs and 4 low-flow pigs were performed. Representative exam-
ples of images from these studies appear in part A. Ponceau red (below the
eNOS Westerns) was used to correct for loading of protein. Ratios of den-
sities of L/R eNOS bands from the same Western blots appear in part B.
There were no differences in eNOS protein expression in left and right lower
lobe pulmonary arteries in samples obtained from either high- or low-flow
pigs. eNOS, Endothelial nitric oxide synthase; L/R, left/right.
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Dafter anastomosis, whereas the opposite relationship was
true in pulmonary arteries from low-flow hosts (Figure 1).
We tested the contribution of NOS to differential reactivity
by treatment 30 minutes before constriction with U46619
with the L-arginine analog L-NMMA (103 mol/L), which
stereospecifically inhibits NOS.8 L-NMMA increased base-
line- and U46619-generated tension in rings from both the
left and right lower lobe pulmonary arteries derived from
either high- or low-flow hosts (Figure 1, A and B). Although
inhibition of NOS lessened, it did not eliminate the differ-
ence in tension between left and right pulmonary arteries
of high- or low-flow hosts.
There was no difference in expression of eNOS protein in
matched pulmonary arteries from left relative to right lower
lobes of either high-flow or low-flow hosts (Figure 2). There
were also no differences in eNOS protein density in high-
flow relative to low-flow hosts.
Inhibition of Arachidonic Acid Metabolites
Decreased Contractility Induced by High Flow
See Figure 3, A, for a schematic of major arachidonic acid
metabolites, their vasoactive effects on pulmonary arteries,
and the site of action of inhibitors. Contractility to U46619
in left and right lower lobe pulmonary arteries from high-
flow hosts was examined in the presence of a cocktail
containing inhibitors of the 3 enzymes that metabolize
arachidonic acids to vasoactive derivatives versus vehicle.
The cocktail contained (1) the COX inhibitor indomethacin
(100 mmol/L) to block COX-1 and 2,9 (2) the cytochrome
P450 (CYP) inhibitor dibromo-dodecynyl-methylsulfimide
(DDMS), 20 mmol/L,10 and (3) the LOX inhibitor NDGA
(20 mmol/L).11 In the presence of the cocktail, the pulmo-
nary arteries from both the right and left (shunted) lobes ofThe Journal of Thoracic and Cathe lung of high-flow hosts constricted to the same extent
to U46619 (Figure 3, B). Next, each inhibitor was tested in-
dividually (Figure 3, C and D).rdiovascular Surgery c Volume 141, Number 2 427
FIGURE 3. A, This schematic depicts 3 major pathways of arachidonic acid metabolism, the dominant vasoactive effects of metabolites of this pathway, and
the site of action of inhibitors we used in these experiments. The blue box shows products that are (1) blocked by NDGA and CDC, (2) reported to increase the
tone of pulmonary arteries, and (3) synthesized in increased amounts by right pulmonary arteries contralateral to systemic pulmonary shunts (see Figure 5). B,
U46619 concentration response curves of pulmonary arteries from high-flow pigs treated with vehicle or an inhibitor cocktail that included indomethacin
(100 mmol/L), DDMS (20 mmol/L), and NDGA (20 mmol/L) for 30 minutes were obtained. The concentration response curves of left and right lower
lobe pulmonary arteries after treatment with the cocktail of inhibitors were not different (n ¼ 6; P> .5, 2-way repeated measures analysis of variance).
C, Treatment with indomethacin (100 mmol/L) or DDMS (20 mmol/L; inset) did not eliminate the differences in contractility of right and left lower lobe pul-
monary arteries to U46619 (n ¼ 5; P< .05 by 2-way repeated measures analysis of variance). D, Treatment with NDGA (20 mmol/L) or CDC (10 mmol/L;
inset) eliminated the differences between reactivity of left and right lower lobe pulmonary arteries to U46619 (n ¼ 6 each). Contraction of left lower lobe
pulmonary arteries was unaffected by NDGA treatment relative to controls, whereas reactivity of the right lower lobe pulmonary arteries was significantly
decreased by this inhibitor (n ¼ 6; P < .05 by analysis of variance). AA, Arachidonic acid; PA, pulmonary artery; DDMS, dibromo-dodecynyl-
methylsulfimide; NDGA, nordihydroguaiaretic acid; CDC, cyanocinnamate; CYP, cytochrome P450; HETE, 12-hydroxyeicosatrienoic acid; EET, epoxyei-
cosatrienoic acids; PG, prostaglandin; TxA2, thromboxane A2; NDGA, nordihydroguaiaretic acid.
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FIGURE 4. Western blots for 15-LOX2 were performed on homogenates of microdissected pulmonary arteries from left and right lower lobe pulmonary
arteries, and densities of immunospecific bands for these proteins and beta actin were compared (n ¼ 6 samples from left and right lower lobe pulmonary
arteries each). The ratio of actin-normalized 15-LOX2 protein density was higher in left than right pulmonary artery homogenates by a factor of roughly
2 (P< .05; n ¼ 6). LOX, Lipoxygenase; IDV, independent diversity values. *P< .05 left relative to right.
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DDecreased Contractility Induced by High Flow Is Not
Mediated by Differences in COX or CYP Activity
Pulmonary artery rings were treated with indomethacin
(COX inhibitor) or DDMS (CYP inhibitor) alone and then
contracted with U46619 (1010–107 mol/L). Higher
tensions in high-flow pulmonary arteries from the right
lower lobe were still observed (Figure 3, C). Thus, although
COX or CYP may contribute some to the differences in con-
tractility of shunted and nonshunted pulmonary arteries,
these metabolites do not appear to have a large effect on
this end point.
Changes in Contractility Induced by High Flow Are
Mediated by Changes in LOXs
A third inhibitor in the cocktail, NDGA (10 mmol/L,
Figure 3, D), substantially eliminated the difference in
contraction between shunted and control lung pulmonary ar-
teries. Similarly, a second LOX inhibitor, CDC (10 mmol/L;
Figure 3, D, inset), eliminated the difference between con-
traction of left and right pulmonary arteries from high-flow
hosts as well.
Western blots of pulmonary artery homogenates from left
and right lower lobes of high-flow hosts were probed with
primary antibodies for 5-LOX, 12-LOX, 15-LOX1, and
15-LOX2. Expression of 5- and 12-LOX as well as 15-
LOX1 was not different between samples from left and right
lower lobe vessels (data not shown). The density of 15-LOX2
was increased in left pulmonary arteries over that of right pul-
monary arteries from high-flow hosts (Figure 4).
14C Metabolites of Arachidonic Acids
We next investigated arachidonic acid metabolism of mi-
crodissected pulmonary arteries. Several products were
identified on the basis of elution profiles in control as well
as pulmonary arteries from high-flow hosts. The major prod-
ucts corresponded to 6-keto prostaglandin (PG) F1a,
11,12,15-trihydroxyeicosatrienoic acids (THETAs), 12-
HETE and 15-HETE (see representative chromatograms,
Figure 5). The arachidonic acid metabolite profile of controlThe Journal of Thoracic and Caleft and right pulmonary arteries was identical (not shown).
Compared with synthetic capacity of control pulmonary ar-
teries, both right and left pulmonary arteries from high-flow
hosts exhibited increased prostanoid products, including
peaks that correspond to 6-keto-PGF1a.
In examining high-performance liquid chromatography
products of right and left pulmonary arteries from high-
flow hosts, we observed other differences in metabolites.
Right pulmonary arteries from high-flow hosts produced
more 12-HETE (P<.05) than control right or left pulmonary
arteries (10.5  1.3, 6.7  0.7 and 6.5  0.9 cmp/mg pro-
tein, respectively (n ¼ 5 each). Synthesis of this product
was decreased by more than 80% in samples incubated
with 10 mmol/L CDC compared with vehicle control.
Enhanced synthesis of a product that comigrated with
15-HETE in 3 of 4 pairs in right compared with left pulmo-
nary arteries was also observed, although this increase was
not statistically significant. Inasmuch as 15- and 12-HETEs
increase the tension in pulmonary arteries,6,12 enhanced
HETE synthesis in unshunted right pulmonary arteries is
a good candidate to mediate increased tension to U46619.
DISCUSSION
We have observed endothelium-dependent enhanced reac-
tivity of pulmonary arteries contralateral to a high-flow/high-
pressure shunt 48 hours after creation of a localized anastomo-
sis (Figure 1, A). Therefore, the investigations in this article
focused on identification of endothelium-derived contracting
factors that were overexpressed or prodilatory factors that
were decreased in unshunted relative to shunted pulmonary
arteries in this model. In this regard, several endothelium-
derived products including NO, prostacyclin, and 20-HETE
are reported to cause vasorelaxation in the pulmonary circula-
tion.3,13,14 Of these products, both prostacyclin and NO are
augmented by exposure to high flow.15,16 Similarly,
endothelium-derived epoxyeicosatrienoic acids, endothelin-
1, thromboxane, and LOX products, have pulmonary vaso-
constrictive properties.6,17,18 Our studies show for the first
time that enhanced constriction of unshunted pulmonaryrdiovascular Surgery c Volume 141, Number 2 429
FIGURE 5. Arachidonic acid metabolism in isolated pulmonary artery segments. A representative chromatogram from a pair of shunted and unshunted pul-
monary arteries of high-flow pigs (see legend for identification code) is shown. Migration times of known standards are indicated. Results were normalized to
vessel weight and expressed as cpm/mg. A peak that elutes at 20 to 21 minutes (fractions 100–105) coincident with authentic 12-HETE is higher in the right
pulmonary artery sample. AA, Arachidonic acid; HETA, hydroxyeicosatrienoic acid; RPA, right pulmonary artery; LPA, left pulmonary artery.
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Darteries to U46619 relative to that of control pulmonary
arteries or those distal to the anastomosis is eliminated by 2
different inhibitors of the LOX pathway, but not by
inhibitors of COX, CYP, or NOS. Coupled with evidence
of increased synthesis of LOX products in unshunted
pulmonary arteries over that of controls, these data suggest
a role for enhanced production of vasoconstrictive LOX
products in promoting a proconstrictive state in these
arteries. We believe our data are also the first to
demonstrate flow-induced changes in products of small
arteries remote (in fact contralateral) to a localized shunt
and differences in reactivity based on these differences in me-
tabolite production.
Increased contractility of right lower lobe pulmonary ar-
teries in our high-flow model was not attributable entirely
to a decrease in eNOS activity because after inhibition of
NOS by L-NMMA, the right remained significantly more re-
active than the left. Similarly, eNOS-immunospecific protein
was not different in left and right lower lobe pulmonary ar-
teries 48 hours after anastomosis. These observations do
not exclude flow-induced alterations in eNOS expression or
activity before or after 48 hours or eNOS uncoupling in con-
tribution to enhanced constriction in unshunted pulmonary
arteries.1 In fact, eNOS uncoupling may well occur in pulmo-
nary arteries distal to the shunt, but be masked by either en-
hanced eNOS expression or upregulation of some other
mediator that balances the effects of eNOS uncoupling.
On the other hand, a cocktail that included inhibitors of all
3 major pathways of arachidonic acid metabolism elimi-430 The Journal of Thoracic and Cardiovascular Surgnated the differences in the U46619 response curve of right
and left lower lobe pulmonary arteries. When these inhibi-
tors were tested individually, only the LOX inhibitors
NDGA or CDC decreased response of right lower lobe
pulmonary arteries to U46619 to that of their left lower
lobe counterparts. NDGA is a LOX inhibitor with activity
against cysteinyl-leukotriene synthesis with 50% inhibitory
concentrations less than 10 mmol/L for 5-, 12- and 15-LOX
in human pulmonary artery endothelial cells.19 Similarly,
CDC has IC50 less than 3 mmol/L for 5-, 12-, and 15- in iso-
lated enzyme preparations.20 Thus the concentrations of
both NDGA and CDC used in these investigations should
have effectively inhibited cysteinyl-leukotriene synthesis
from all 3 isoforms in the ex vivo pulmonary arteries.
To evaluate the potential contribution of differential
expression of LOX to the reactivity profile, we performed
Western blots of homogenates of microdissected pulmonary
arteries probedwith antibodies to5-LOX,12-LOX,15-LOX1,
and 15-LOX2. We observed no differences in density of 5-,
12-, or 15-LOX1, but an increase in 15-LOX2 expression in
shunted left over right pulmonary arteries. In humans, 15-
LOX1 and 15-LOX2 are derived from 2 different genes.21,22
The enzymes display tissue- and cell-specific expression
patterns. The dissimilar expression of isoform-specific
15-LOXs in these investigations may relate to differences in
reactivity of shunted and nonshunted pulmonary arteries, but
further studies are necessary to confirm this observation.
We also examined eicosanoid metabolism in ex vivo pul-
monary arteries. Our data demonstrate enhanced productionery c February 2011
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Dof 12-HETE in hypercontractile pulmonary arteries contra-
lateral to localized shunts. LOX products are known to
mediate vasoreactive responses in the lung. Inhibition of
5-LOX–activating protein reduces pulmonary vascular reac-
tivity and hypertension in hypoxic rats, and mice bred with
the deletion of 5-LOX developed less right heart hypertro-
phy to hypoxia than their matched wild-type counterparts.23
Similarly 15-HETE, a product of 15-LOX, causes
concentration-dependent contraction of pulmonary artery
rings in rabbit kits exposed to hypoxia.6 CDC blocks the in-
creased reactivity of right over left pulmonary arteries and
decreases the synthesis of 12-HETE. Together, our data
position enhanced production of 12- or 15-HETE derived
from pulmonary arteries contralateral to a localized shunt
as a good candidate for mediating increased reactivity of
these arteries. They do not exclude potential contributions
of other systems that modulate pulmonary vascular tone,
such as endothelin.
In summary, we demonstrated increased reactivity of un-
shunted right over shunted left pulmonary arteries elimi-
nated by LOX inhibitors NDGA and CDC and enhanced
production of LOX product 12-HETE in these same pulmo-
nary arteries with enhanced reactivity. These unexpected
findings may have clinical implications in conditions such
as traumatic or naturally occurring systemic–pulmonary
artery fistulas24 or increased global pulmonary vascular re-
sistance in conditions of isolated aortic origin of the right
pulmonary artery.25 In addition to primary effects of high
flow on shunted pulmonary arteries, our studies suggest
that careful investigations of flow effects on eicosanoid
synthesis of pulmonary arteries remote and distal to localized
shunts should be undertaken. Eicosanoid products of pulmo-
nary arteries contralateral to a localized shunt may contribute
to enhanced generalized pulmonary vascular resistance.
We acknowledge the significant contributions of Drs Bousamra,
Nirula, Friesema, and Zhu, as well as Stephanie Gruenloh to the
works in this communication.
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